Protein and Drug Biochemistry

The Protein and Drug Biochemistry Unit’s expertise lies in the purification of bacterial, plant and animal proteins, target proteins and their chemical and enzymological characterization. Applied methods range from protein chromatography to spectroscopic analysis of protein structure and mechanisms of enzyme functions. The unit’s competence also encompasses the isolation and characterization of antibodies aiming at developing protein drugs as well as their semi-preparative extraction. The subsequent structure-activity-analysis as well as structure-based molecular optimization complement the unit’s portfolio.

Therapeutic antibodies against active chemokines

Chemokines are signal proteins or peptides secreted by cells, which direct the movement of responding immune cells. The secretion of inflammatory cytokines is induced by inflammatory processes and pathogens. This causes the recruitment of leucocytes along a concentration gradient to the source of chemokine production. Dysregulation of chemokines plays a destructive role in many chronic inflammatory diseases like arthritis, multiple sclerosis and colitis. Due to the high presence of chemokines, originally providing the clearance of pathogens and damaged tissue, enhanced influx of immune cells causes attack of endogenous healthy structures in these diseases.

After cleavage of the signal peptide, some chemokines possess an N-terminal glutamine residue, which is subsequently converted to pyroglutamate under physiological conditions by glutaminyl cyclase activity. The resulting lactam ring is not protonated in the physiological pH range. This provides an elevated resistance against aminopeptidases and exoproteases, which need a protonated amino group for substrate binding.

Furthermore, enhanced receptor activation could be shown for the respective chemokines after N-terminal pyroglutamate formation. Chemokine cleavage by endoproteases, like matrix metalloproteinases, is not affected by an N-terminal pyroglutamate. However, it was described that truncation of chemokines by matrix metalloproteinases results in receptor antagonists, which are able to bind, but fail to activate the chemokine receptor.

Our approach is the development of protein drugs, which neutralize post-translationally modified chemokines. Besides the N-terminal modifications, also other structural elements might be important. In addition to antibodies, therapeutic proteins with antibody like properties will be developed in cooperation with industry partners.

Targeting post-translational protein modifications to treat neurodegenerative disorders

Neurodegenerative diseases are characterized by the progressive loss of brain substance. The degeneration of nerve cells coincides with the development of dementia, i.e. a qualitative and quantitative decline of brain cognitive performance. Due to the rise of life expectancy, dementia, especially Alzheimer Disease (AD), will pose a major challenge to our health systems in the decades to come. Prevalence rates in Germany identify 1.4 million diseased individuals, numbers worldwide approximate 44 million and are expteced to triple by the year 2050. Despite the fact that some medication is available to extenuate the symptomes of the diseases, no curative therapy is on hand right now.

The majority of neurogenerative diseases is ascribed to a misfolding of proteins. This structural modification results in an aggregation that damages the surrounding tissue and cells causing them to die off. An effective therapy needs to prevent the peptides from aggregation and to accelarate the decomposition of these proteins respectively.

Latest research findings show that various proteins are prone to structural changes (posttranslational modification), which often accelerates their deposition. Such modifications are, among others, N-terminal pyroglutamate and Isoaspartat formation, nitroyslation or phosphorylation.

This projects aims at identifying posttranslational modifications in deposited proteins that characterize the particular neurogenerative disease. The formation of the modification as well as strategies for its supression are under investigation. New substances may either prevent the modification of proteins (enzyme effectors) or target the modified proteins by binding to accelarate their degradation (protein drugs).

  • Molecular cloning procedures for expression vector generation
  • Heterologous expression of target proteins in E. coli, yeast, insect and mammalian cells
  • Protein purification in analytical and small preparative scale
  • Spectroscopic analysis of enzyme structure and function in vitro (UV-Vis, CD, and fluorescence chemoluminescence spectroscopy), development of enzyme assays
  • Structure- based optimization (protein engineering) of antibodies

  • Hartlage-Rübsamen M, Waniek A, Meissner J, Morawski M, Schilling S, Jäger C, Kleinschmidt M, Cynis H, Kehlen A, Arendt T, Demuth HU, Rossner S. Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease. Acta Neuropathologica 2015; 129(4): 565-583. DOI dx.doi.org/10.1007/s00401-015-1395-2
  • Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, Roßner S. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer‘s disease. Journal of Alzheimer‘s Disease. 2014;39(2):385-400. DOI dx.doi.org/10.3233/JAD-131535.
  • Güttler BH, Cynis H, Seifert F, Ludwig HH, Porzel A, Schilling S. A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues. 2013 Apr;44(4):1205-14. DOI dx.doi.org/10.1007/s00726-012-1454-0. Epub 2013 Jan 24.
  • Nussbaum JM*, Schilling S*, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-?. Nature. 2012 May 2;485(7400):651-5. DOI dx.doi.org/10.1038/nature11060
  • Schilling S, Kohlmann S, Bäuscher C, Sedlmeier R, Koch B, Eichentopf R, Becker A, Cynis H, Hoffmann T, Berg S, Freyse EJ, von Hörsten S, Rossner S, Graubner S, Demuth HU. Glutaminyl cyclase (QC) knock out mice show mild hypothyreodism but absence of hypogonadism: implications for enzyme function and drug development. J Biol Chem. 2011 Apr 22;286(16):14199-208. DOI dx.doi.org/10.1074/jbc.M111.229385
  • Seifert F, Schulz K, Koch B, Manhart S, Demuth HU, Schilling S. Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates. Biochemistry. 2009 Dec 22;48(50):11831-3. DOI dx.doi.org10.1021/bi9018835
  • Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med. 2008 Oct;14(10):1106-11. DOI dx.doi.org/10.1038/nm.1872